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Introduction
Triple-negative breast cancer (TNBC) is a breast cancer phenotype characterized by an immunohistochemical absence of estrogen receptor (ER) and progesterone receptor (PR), as well as absence of amplification of the human epidermal growth factor receptor 2 (HER2) gene [1] . Due to tumor heterogeneity and presence of several subtypes, TNBC is of particular concern; it is clinically aggressive compared to other breast cancers, has poor prognosis on overall survival (OS) and disease-free survival (DFS), lacks specific target for therapeutic intervention, and overlaps with BRCA1-associated breast cancers. [2] Approximately 10-20% of all breast cancers are TNBC [3] [4] [5] and the prevalence is high in Asians [6, 7] . Data on the prevalence of TNBC in Thailand is sparse but in a recent study on survival time in breast cancers of different molecular subtypes, >30.0% of study patients were found to have TNBC [8] . There has been an increasing incidence of breast cancer in Thailand in recent years [9, 10] and this indicates that TNBC-related morbidity and mortality will certainly rise in the future.
Currently the mainstay of TNBC treatment is surgery with or without adjuvant chemotherapy [11] and the choice of therapeutic approach depends on the level of advancement of the disease. Early-stage TNBC is shown to have high sensitivity to adjuvant chemotherapy [12] and is associated with an improvement in DFS and OS [13] . In these patients, depending on their performance status, anthracycline-and taxane-based regimens are the standard of care while docetaxel in combination with cyclophosphamide is considered as an acceptable nonanthracycline-based adjuvant chemotherapy [13] [14] [15] . On the other hand, treatment of metastatic TNBC (mTNBC) follows the general principles for all metastatic breast cancers and is largely palliative instead of curative [16] . The main goal of chemotherapy in mTNBC is to prolong progression-free survival (PFS) and OS as well as to improve patients' quality of life. Currently, there is no first-line standard of care for treatment for mTNBC, and due to the lack of clinical success of targeted therapies, the most common approach involves the use of taxanes, anthracyclines, vinca alkaloids, and antimetabolites, either as a single-agent or multiple agents in combination or sequential manner [1, 17] .
In order to implement evidence-based strategies in cancer medicine and introduce newer therapies and regimens, it is necessary to first assess the existing standard practices and identify any shortcomings in these. Hence, the primary objective of the study was to characterize clinical patterns of newly diagnosed TNBC patients in Thailand in real-life practice. Secondary objectives included identification of existing treatment patterns and assessment of 3-year survival rates in study patients.
Materials and methods

Study design
The reported study was a national, multicenter, non-interventional, prospective cohort analysis with a three-year follow-up.
The study included four patient visits over three years-an inclusion visit (V0) during which the patient was enrolled, and subsequent yearly visits (V1-V3) at 12 ± 1 months, 24 ± 1 months, and 36 ± 1 months after completion of first day of chemotherapy.
The 
Patient recruitment and data collection
Patient recruitment for the study began in July 2011 and the last patient finished their last follow-up visit in January 2016. Study patients were females (aged �18 years) with histologically documented TNBC fulfilling the following criteria: 1) ER negative (ER-ve), and PR negative (PR-ve), defined by <1% tumor staining by immunohistochemistry (IHC), and 2) HER2 non-overexpression, defined by IHC score of (0,1) or fluorescence in situ hybridization-negative (FISH-ve), or silver in situ hybridization-negative (SISH-ve). In addition, study patients were not to have received prior chemotherapy for their TNBC (adjuvant or neoadjuvant chemotherapy for early-stage TNBC or chemotherapy for metastatic TNBC). Patients presenting with in situ breast carcinoma, or were non-TNBC, or had a concurrent history of other neoplasm (except curatively treated basal cell skin cancer or adequately treated in situ cervical carcinoma) were excluded from the study.
Data collected at baseline (V0) included patient demographics, relevant medical history, circumstances of detection, tumor characteristics, TNM staging (AJCC 7 th Ed), treatmentsprior and planned, factors influencing planned treatment (classified into tumor factor, subject factor, and center factor). Data collected at V1-V3 included performance status according to Eastern Cooperative Oncology Group (ECOG) scores, treatments received, treatments ongoing and reasons for change in planned treatment (only V1), date and pattern of recurrence, and patient survival status-OS, DFS, and PFS.
Statistical analysis
Calculation of sample size was made after taking in consideration the national incidence in 2010 in Thailand of 13,310 new breast cancer cases, of which 11% (1471 cases) were estimated to be TNBC. In order to enroll approximately 20% of the annual TNBC cases and allowing for a 10% annual dropout rate, a total of 300 TNBC patients were targeted as the sample size for enrolment into the study.
Statistical methods
Study variables were analyzed using descriptive statistics-mean, standard deviation (SD), median, range, and 1 st and 3 rd quartiles for continuous parameters, and counts and percentages for categorical parameters. Survival curves were designed using Kaplan-Meier method and stratified by ECOG scores and tumor burden. Statistical significance between chemotherapy regimens was calculated using log-rank test. All analyses were performed with SAS version 9.4 (SAS Institute, Cary, North Carolina).
Subgroup and post hoc analyses
Certain subgroup analyses were carried out to ascertain the effects of anthracycline and taxane regimens; specifically, taxane vs. non-taxane, and anthracycline vs. non-anthracycline. Moreover, post hoc analyses were carried out to assess the effect of taxane add-on to anthracyclinebased adjuvant chemotherapy in Stage III patients. Data were analyzed for median follow-up period, median DFS and OS, as well as for survival probability at one, two, and three years following enrollment. . The proportion of patients with a family history of breast cancer and ovarian cancer was 8.2% (n = 24) and 1.4% (n = 4), respectively. Over half (n = 177, 60.4%) of the study patients were postmenopausal.
Results
Patient disposition and characteristics
The commonly employed methods for breast cancer detection were core biopsy, excisional biopsy, and diagnostic mammogram, employed in 41.8% (n = 122), 31.5% (n = 92), and 18.8% (n = 55), of the patients, respectively.
All patients (N = 293) were diagnosed with ductal carcinoma. Overall, TNBC tumors were moderately to poorly differentiated Table 1 . In early-stage patients, tumors were mostly poorly differentiated (49.6%, n/N = 130/262) or moderately differentiated (41.2%, n/N = 108/262). In patients with mTNBC, the majority of the tumors were either not assessable (45.2%, n/N = 14/ 31) or poorly differentiated (35.5%, n/N = 11/31).The most common sites of metastasis in patients with mTNBC were lungs (n = 13), liver (n = 6), and bones (n = 6).
Almost 90.0% (n/N = 262/293) of the patients had undergone breast surgery prior to enrollment, the majority (77.1%, n = 226) of which was total mastectomy Table 1 . Mean number of nodes excised and nodes positive for malignancy were 16.5 (±8.1) and 2.8 (±5.6), respectively. Eight (25.2%) patients with mTNBC received radiation therapy prior to enrolment, either as curative or palliative. The most common site for radiation was the supraclavicular region (n = 6).
The mean (± standard deviation [SD]) size of the primary tumor in patients was 31.59 (±21.12) mm. Seven patients presented with a second tumor, with a mean (±SD) size of 20.00 (±10.03) mm. Only one patient presented with a third tumor (size: 8 mm) S1 Table. Approximately half (51.9%, n/N = 136/262) of early-stage patients were assessed by the study investigator to have an intermediate risk of recurrence (tumor size > 1 cm., node negative) within the next three years. Moreover, 42.4% (n/N = 111/262) of the early-stage patients were judged to be at high risk of recurrence (node positive � 1 node) in the same timeframe. In early-stage patients, chemotherapy was prescribed as either neoadjuvant (n = 17, 6.8%) or adjuvant therapy (n = 233, 93.2%) Table 2 . The most favored adjuvant combination in early-stage TNBC patients was doxorubicin/epirubicin with cyclophosphamide (AC/EC: 23.6%, n/N = 59/250), followed by fluorouracil, doxorubicin/epirubicin, and cyclophosphamide [FAC/FEC/CAF/CEF; 22.4% (n = 56)]. The most favored adjuvant sequential chemotherapy was AC/EC prior to taxanes [AC/EC-� paclitaxel (12.4%, n = 31) and AC/EC-> docetaxel (8.4%, n = 21)]. Twelve (4.6%) of the early-stage patients did not receive any chemotherapy, because of non-specified reasons (n = 6), patient's decision to not receive it (n = 5), and having completed chemotherapy prior to study inclusion (n = 1).
All patients with mTNBC received chemotherapy, either as a combination, or as a single agent, or in a sequential manner Table 3 . The most commonly prescribed chemotherapeutic 
Disease-free Survival (in early-stage patients)
At 3-years, 94% of stage I and 80% of stage II patients survived the study without disease, hence, the median DFS could not be computed for these two groups of patients. While for Stage III patients, the median DFS was found to be 37.0 months (Fig 1A) .
No statistically significant difference in DFS in early-stage patients was observed when analyzed by factoring in taxane versus non-taxane chemotherapy (p = 0.2931). This pattern was also repeated for sub-group analysis based on tumor staging.
Similarly, no statistically significant difference in DFS in early-stage patients was apparent when analyzed for anthracycline versus non-anthracycline-based chemotherapy (p = 0.9162). Furthermore, this lack of difference in DFS was repeated for Stage I and II patients when probed for anthracycline-based chemotherapy. However, in Stage III patients, median DFS was found to be longer in patients receiving anthracycline-based chemotherapy (DFS 37.0 months vs. 13.5 months in patients who received non-anthracycline-based treatment; p = 0.0181, S4 Fig. 
Progression-free Survival (in patients with mTNBC)
The median PFS in patients with mTNBC was found to be 10.0 months (IQR: 7.0-13.0 months), Fig 1B. The PFS was found to be longer in patients who received non-taxane-based chemotherapy in comparison to those who received a taxane-based chemotherapy (12.5 months vs. between patients who received anthracycline-based chemotherapy in comparison to those who were administered a non-anthracycline-based chemotherapy.
Overall survival
The 3-year survival rate in early-stage patients was calculated to be 85.0%. In contrast, this survival rate in patients with mTNBC was 21.0% (Table 4 and Fig 2) . Median OS had not been In patients with mTNBC, the median OS was shorter in taxane-based regimen than those who received non-taxane-based regimen (11.00 months vs. 15.50 months; p = 0.3042), although the difference is not statistically significant. In contrast, the median OS in patients with mTNBC who received anthracycline-based regimen was statistically non-significantly longer than that of a non-anthracycline-based regimen (15.00 months vs. 11.50 months; p = 0.7403).
Effects of taxane add-on to anthracycline-based adjuvant chemotherapy
A total of 14 Stage III patients received anthracycline-based adjuvant chemotherapy and of these, three patients were lost to follow-up or withdrew consent. A total of 30 patients received a taxane add-on sequential or combination to anthracycline-based adjuvant chemotherapy.
Median DFS and OS in Stage III patients who received only anthracycline-based chemotherapy was calculated as 20.0 months and 32.0 months, respectively (Fig 3) . On the other hand, in Stage III patients who had received taxane add-on, median DFS and OS could not be reached since approximately 70% of the patients were alive at the end of study period.
Discussion
To the best of our knowledge, the reported study is the first of its kind in Thailand to specifically characterize clinical pattern and real-life practices in management of early-stage and metastatic TNBC and assess 3-year survival. Of the 293 patients enrolled in our study, the majority (89.4%) presented early-stage TNBC, mostly Stage II disease. In patients presenting mTNBC, the most common site of metastasis was the lung. Slightly more than half of the early-stage patients were judged to be at a risk for recurrence in three years. Over 95.0% of the patients received adjuvant chemotherapy and anthracycline-based regimens were the adjuvant chemotherapy of choice. During the course of study, survival rate declined with disease progression and was approximately 21.0% in patients with mTNBC in comparison to 100.0% in Stage I patients. Anthracycline-based and non-taxane-based chemotherapeutic regimens were found to have a positive effect on DFS in early-stage TNBC and PFS in mTNBC, respectively. The lack of receptors that are responsive to hormonal therapy or trastuzumab therapy is a major drawback for the treatment of TNBC [2] . Therefore, currently available options range from surgery in locoregional disease and palliative chemotherapy for progressive TNBC [17] . In our patients, prior surgery was widely reported as first line of treatment; in 91.6% of earlystage patients and 71.0% of patients with mTNBC. However, we could not discern at what stage the choice of surgical intervention in patients mTNBC was made i.e. if surgery was conducted prior to metastasis. Furthermore, total unilateral mastectomy, often without reconstruction, was reported as the commonly used surgical technique.
The current options for adjuvant therapy for early-stage TNBC are anthracycline-and/or taxane-based regimens, usually in combination with cyclophosphamide. Another classical combination that is reportedly active against TNBC is cyclophosphamide + methotrexate + fluorouracil (CMF) [18] . Neoadjuvant anthracycline-based chemotherapy against TNBC is shown to result in pathological complete response and improvement in survival [19] . However, the superiority of anthracycline-based chemotherapy over CMF in an adjuvant scenario is somewhat contentious [20] since conflicting results have been published [21, 22] . In our study, prescription of neoadjuvant chemotherapy was negligible, and the majority of our patients received adjuvant chemotherapy. The most commonly prescribed chemotherapeutic regimens, in both early-stage patients and in patients with mTNBC, were anthracycline-based, either as a combination with cyclophosphamide and/or fluorouracil or as a sequential regimen with taxanes. Real-life assessment of TNBC in Thailand Survival rates in patients with TNBC are generally poorer in comparison to those with other breast cancers. Moreover, as in other cancers, a host of independent factors such as tumor stage, molecular composition of the tumor, locoregional advancement, metastatic progression, and choice of treatment govern survival outcomes in TNBC. Hence, it becomes tenuous to compare data gathered in different observational registries. However, any such academic endeavor does provide an overview on real-life outcomes of clinical practices elsewhere. In our study, the 3-year survival rate in early-stage TNBC patients was found to be 85.0%. In contrast, data from the substantially larger California Cancer Registry revealed a 5-year survival rate of 77.0% in patients with TNBC [23] . However, these findings need to be put in perspective, largely because of the shorter time-span of our study and our inability to confirm whether the data from the California Cancer Registry were exclusively for early-stage TNBC patients or if they included mTNBC patients. Of particular interest in our study is the observation on DFS in early-stage TNBC patients: the Stage I and II patients had not achieved median DFS (>50.0% surviving without the disease) wherein median DFS of in Stage III patients was calculated to be 37.0 months. Since the highest probability of disease relapse in TNBC patients is within the first three years after primary treatment [24] and despite a substantial proportion of our early-stage patients were judged to be at high risk of recurrence at enrolment, the observed DFS values are encouraging. In case of patients with mTNBC, we reported an overall PFS of 10.0 months and this was slightly longer in patients who had received non-taxane-based regimens (PFS: 12.5 months). However, when we take into consideration the notable disparity in the numbers of patients who received taxanes or not, it is difficult to draw a conclusion regarding the effectiveness of one regimen over the other.
In our study, median OS in patients with mTNBC was calculated to be 14.0 months and this is comparable to the 9.0-13.3 months OS that has been previously reported [25, 26] . Though not statistically significant, we observed that median OS was longer in those patients with mTNBC who had received a non-taxane-based regimen in comparison to those who had received a taxane-based regimen; and in patients who had received an anthracycline-based regimen in comparison to those who had received a non-anthracycline-based regimen. The PFS was also found to be longer in patients with mTNBC who received non-taxane-based chemotherapy in comparison to those who received a taxane-based chemotherapy. However, our study was not powered enough, i.e. lacked enough patients in each subgroup to establish the validity of this observation. Moreover, patients with mTNBC tended to have received various chemotherapeutic regimens when the preceding one failed to elicit a satisfactory response and hence it is not possible to attribute the net effects to a single regimen.
The use of anthracycline-based chemotherapy with add-on taxanes in neoadjuvant settings has been shown to result in increased pathological complete response in patients with early-stage TNBC [19] . However, the utility of this regimen in adjuvant settings against TNBC has not been convincingly proven. Certain reports have concluded that adjuvant docetaxel or paclitaxel improves DFS and OS [27, 28] . On the other hand, certain studies have failed to recapitulate any advantage to add-on taxanes [29, 30] . We conducted post hoc analyses on our study data to probe for any association between survival in Stage III TNBC patients and addition of taxanes to anthracycline-based adjuvant chemotherapy. Our results show a notable improvement in DFS and OS in Stage III patients who had received a taxane sequential to anthracycline-based chemotherapy; median DFS and OS in patients who had received only anthracycline-based chemotherapy were 20.0 and 32.0 months, respectively, while in patients with taxane add-on median DFS and OS had not been reached at the time of study conclusion. These findings are interesting but must be interpreted with caution since the group size was small, therefore, the robustness of the analyses may be limited. Large-scale studies will be required to ascertain whether add-on taxanes to adjuvant chemotherapy have a decided beneficial effect on the treatment of TNBC in Thai settings.
Being an observational study, our investigation was limited in its scope. Survival outcomes in TNBC depend intrinsically on a number of factors including treatment strategy employed. In our study, we could analyze survival data only according to the class of chemotherapeutic agent i.e. taxane versus non-taxane and anthracycline versus non-anthracycline. Hence, we could not identify any particular regimen as more effective than others. Moreover, despite our observed improvements in survival outcomes in early-stage patients who had received anthracycline-based regimen, we advise caution in interpreting these results because of the large proportion of patients who received anthracycline-based treatments. Certain endpoints such as median DFS and OS were not attained for early-stage patients and hence further follow-up was required to identify the impact of current therapeutic practices on survival in Thai patients. However, despite these shortcomings, our study does provide a snapshot of the reallife management of TNBC in Thailand. Our findings highlight the need for further studies to evaluate the effectiveness of contemporary treatment practices in Thailand and could be useful in developing newer and more efficient strategies for treating Thai patients with TNBC. 
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